Pancreatic cancer has a grim prognosis. It is usually detected after the disease has spread, and chemotherapy tends to do little to slow the cancer’s growth. Even with treatment, most patients live only about six months after they are diagnosed with the disease.
Researchers in Professor David Tuveson’s laboratory at Cold Spring Harbor Laboratory (CSHL) think it’s possible to do better with a different type of treatment. Part of the problem, they say, is that cancer cells in the pancreas are protected by the dense matrix that surrounds them. The matrix is a mixture of extracellular components and noncancerous cells known as the stroma. All solid tumors contain stroma. In pancreatic cancers, this fibrous material is particularly abundant, making up nearly 90 percent of a tumor’s mass. This stroma impedes anticancer drugs’ from getting to their targets. Additionally, stromal cells secrete factors that actually help the tumors grow.
Overcoming the stroma’s protective influence has been challenging, but new leads from Tuveson’s team, as reported on October 26, 2018 in the journal Cancer Discovery, point to a promising strategy. In fact, the new findings suggest that drugs which target the right cellular pathways can do more than just thwart tumor-supporting cells in the stroma. They may recruit them into the anticancer fight.
A key element of the stroma is a type of cell called a fibroblast. Fibroblasts manufacture the stroma’s connective tissue. They also generate factors that promote cancer cell growth and prevent the immune system from attacking the cancerous cells. Last year Tuveson’s team discovered that the stroma of pancreatic tumors contains at least two types of fibroblasts. One type show features known to support tumor growth, the other type appear to have the opposite effect.
The good news is that the fibroblasts’ identities are not fixed. With the right cues, tumor-promoting fibroblasts can become tumor-restrictors.
“These cells can convert into one another, depending on the cues they get from the microenvironment and from the cancer cells,” explains Giulia Biffi, a postdoctoral researcher in Tuveson’s lab who led the new study. “This is potentially useful because, in theory, you can shift the tumor-promoting cells to tumor-restraining, rather than just depleting the tumor-promoting cells.”
In this new report, Biffi and her colleagues have identified specific molecular signals released by cancer cells that determine fibroblasts’ character within pancreatic tumors. They have discovered that one such molecule, IL-1, drives fibroblasts to take on a tumor-promoting identity. They have also shown how another molecule, TGF-beta, overrides that signal and keeps fibroblasts in a potentially anticancer state even when IL-1 is present.
The researchers are now exploring what happens to pancreatic tumors when they manipulate IL-1 and TGF-beta signaling and convert tumor-promoting fibroblasts to a more beneficial state. They will also investigate what happens when they target these pathways in combination with chemotherapy or cancer immunotherapies. Ultimately, Biffi says, patients may benefit most from a combination of therapies that target both the cancer cells and parts of the microenvironment that support their growth.
Learn more: Turning cells against pancreatic cancer
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- Nature Communications publishes Bluestar Genomics' technology for cancer detection studyon October 20, 2020 at 11:04 am
Bluestar Genomics, an innovative company leading the development of next-generation epigenomic approaches to early cancer detection, announced today the publication of study results in the ...
- Walk Where You Are and Help Pancreatic Cancer Researchon October 20, 2020 at 9:12 am
LA Cancer Challenge Walk/Run is virtual in 2020; there’s still time to join, get out into your neighborhood, and help others.
- Cliff Ramos, beloved Collins Hill wrestling coach, dies after battle with pancreatic canceron October 20, 2020 at 9:01 am
Cliff Ramos, a beloved high school wrestling coach in Gwinnett County for more than 40 years, died after a battle with pancreatic cancer last week. Ramos mentored more than a thousand young wrestlers ...
- Validation of Bluestar Genomics’ Technology for Non-Invasive Detection of Pancreatic Cancer Published in Nature Communicationson October 20, 2020 at 8:11 am
Novel Epigenomic Approach Provides Proof of Concept for Early Cancer Detection Paving the Way for Next-Generation Screening Tests Bluestar Genomics, an innovative company leading the development of ...
- Rafael Pharmaceuticals’ lead compound CPI-613 on go with early-stage study for pancreatic canceron October 20, 2020 at 7:00 am
Rafael Pharmaceuticals' (RFL +4.5%) partner Ono Pharmaceutical has commenced, a Phase 1 study of Rafael’s lead compound, CPI-613 in Japan for patients with pancreatic cancer.The study will evaluate ...
- A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals’ Lead Compound CPI-613®️ (devimistat) for Patients With Pancreatic Cancer in Japanon October 20, 2020 at 6:09 am
CRANBURY, N.J., Oct. 20, 2020 (GLOBE NEWSWIRE) -- (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics announced today its partner Ono Pharmaceutical Co.
- Prestige Biopharma Receives Positive EMA Opinion on Orphan Designation for PBP1510 for Treatment of Pancreatic Canceron October 18, 2020 at 8:07 pm
Prestige BioPharma Ltd. (hereinafter “Prestige BioPharma”) today announced that the European Medicines Agency (EMA) Orphan Drug Commission (COMP) has ...
- Pancreatic cancer: Subtypes with different aggressiveness discoveredon October 15, 2020 at 10:55 am
Tumors of the pancreas are particularly feared. They are usually discovered late and mortality is high. Until now, no targeted and personalized therapies exist. Scientists at the German Cancer ...
- CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio’s Expanded Phase 2 Study of Pancreatic Cancer Treatmenton October 13, 2020 at 7:13 am
CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today ...
via Bing News